Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

the latter has a “history of taking already known molecules and moving them very quickly through the FDA”

https://www.pharmaceutical-technology.com/features/neurorx-covid-19-respiratory-failure/

This time of year is called “flu season.” In the United States, flu viruses are most common during the fall and winter months. Flu activity often begins to increase in October and November. Most of the time flu activity peaks between December and February, and it can last as late as May.

https://www.cdc.gov/flu/season/faq-flu-season-2019-2020.htm

The global influenza market was valued at nearly $5.6 billion in 2017 and is expected to reach nearly $6.5 billion by 2022, increasing at a compound annual growth rate (CAGR) of 3.0% from 2017 through 2022.

https://www.bccresearch.com/market-research/pharmaceuticals/the-global-influenza-market.html

Per virtual attendee:

*US patent 8178489B2 - May be useful in future applications.
*Cooperative agreement with NIH (NIAD) to test VIP not only against COVID, but also against influenza and other pulmonic viruses.
*BARDA is evaluating for National Stockpile.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158457496